$322 Million is the total value of Foresite Capital Management V, LLC's 17 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 35.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | Somalogic, Inc. | $65,995,000 | – | 5,326,472 | +100.0% | 20.51% | – | |
| CGEM | Cullinan Oncology, Inc. | $61,648,000 | -12.3% | 2,731,410 | 0.0% | 19.16% | -30.8% | |
| New | Adagio Therapeutics, Inc. | $54,094,000 | – | 1,280,640 | +100.0% | 16.81% | – | |
| ACRS | Aclaris Therapeutics, Inc. | $22,648,000 | +2.5% | 1,258,243 | 0.0% | 7.04% | -19.0% | |
| KNTE | Kinnate Biopharma Inc. | $20,143,000 | -1.1% | 875,001 | 0.0% | 6.26% | -21.9% | |
| QSI | Quantum-Si Incorporated | $19,533,000 | -32.0% | 2,342,061 | 0.0% | 6.07% | -46.3% | |
| New | Cue Health Inc. | $13,792,000 | – | 1,167,782 | +100.0% | 4.29% | – | |
| NRIX | Nurix Therapeutics, Inc. | $13,528,000 | +12.9% | 451,522 | 0.0% | 4.20% | -10.8% | |
| GMTX | Gemini Therapeutics, Inc. | $9,838,000 | -37.6% | 2,435,125 | 0.0% | 3.06% | -50.7% | |
| HIMS | Hims & Hers Health, Inc. | $7,969,000 | -30.8% | 1,056,922 | 0.0% | 2.48% | -45.3% | |
| PHVS | Pharvaris N.V. | $6,456,000 | -4.8% | 364,142 | 0.0% | 2.01% | -24.8% | |
| ME | 23andMe Holding Co. | $6,342,000 | -22.5% | 700,000 | 0.0% | 1.97% | -38.8% | |
| FSII | FS Development Corp. II | $5,995,000 | -0.3% | 602,500 | 0.0% | 1.86% | -21.3% | |
| PHICU | Population Health Investment Co., Inc.unit | $5,603,000 | -42.5% | 960,000 | 0.0% | 1.74% | -54.6% | |
| RACB | Research Alliance Corp. II | $4,925,000 | -2.9% | 500,000 | 0.0% | 1.53% | -23.3% | |
| HLXA | Helix Acquisition Corp. | $2,488,000 | -3.9% | 250,000 | 0.0% | 0.77% | -24.1% | |
| LHDX | Lucira Health, Inc. | $760,000 | -76.4% | 485,000 | 0.0% | 0.24% | -81.4% | |
| BCTG | Exit | BCTG Acquisition Corp. | $0 | – | -400,000 | -100.0% | -1.79% | – |
| ALXO | Exit | ALX Oncology Holdings Inc. | $0 | – | -231,200 | -100.0% | -4.97% | – |
| RLAY | Exit | Relay Therapeutics, Inc. | $0 | – | -400,000 | -100.0% | -5.76% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 25.8% |
| Hims & Hers Health, Inc. | 11 | Q3 2023 | 37.5% |
| Aclaris Therapeutics, Inc. | 11 | Q3 2023 | 15.4% |
| Pharvaris N.V. | 11 | Q3 2023 | 5.5% |
| Quantum-Si Incorporated | 9 | Q2 2023 | 11.3% |
| TheseusPharmaceuticals, Inc. | 8 | Q3 2023 | 24.4% |
| Somalogic, Inc. | 8 | Q2 2023 | 20.5% |
| Compass Therapeutics, Inc. | 8 | Q3 2023 | 17.2% |
| Pardes Biosciences Inc | 7 | Q2 2023 | 37.8% |
| Gemini Therapeutics, Inc. | 7 | Q3 2022 | 9.7% |
View Foresite Capital Management V, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-08-31 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-07-19 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-04-06 |
| 4 | 2023-02-22 |
View Foresite Capital Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.